News Releases Year None202120202019201820172016 Date Title Apr 14, 2021 Homology Medicines Announces Presentations at ACMG Annual Clinical Genetics Meeting Apr 12, 2021 Homology Medicines Announces Promotion of Tim Kelly to Chief Operating Officer Apr 07, 2021 Homology Medicines Announces Pricing of Public Offering of Common Stock Apr 06, 2021 Homology Medicines Announces Proposed Public Offering of Common Stock Mar 11, 2021 Homology Medicines Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights Mar 01, 2021 Homology Medicines Regains Worldwide Rights to Ophthalmology Program Based on its In Vivo Nuclease-Free Gene Editing Platform Feb 25, 2021 Homology Medicines to Participate in Upcoming Investor and Patient Advocacy Conferences Feb 08, 2021 Homology Medicines Announces First Presentation of Data with HMI-203 In Vivo Gene Therapy Development Candidate for Hunter Syndrome Jan 06, 2021 Homology Medicines Announces Plans for Three Clinical Programs in 2021 Spanning Phenylketonuria (PKU) and Hunter Syndrome (MPS II)
